Z-100 + Placebo

Phase 3Completed
0 watching 0 views this weekπŸ“ˆ Rising
76
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
βœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Cancer

Conditions

Cervical Cancer

Trial Timeline

Dec 1, 2014 β†’ Feb 25, 2022

About Z-100 + Placebo

Z-100 + Placebo is a phase 3 stage product being developed by Zeria Pharmaceutical for Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02247232. Target conditions include Cervical Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02247232Phase 3Completed

Competing Products

20 competing products in Cervical Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
47
ABP-450AEON BiopharmaPhase 2
44
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
Gemzar (gemcitabine)Eli LillyPhase 3
77
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumabοΌ› famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52